摘要
目的观察阿仑膦酸钠(福善美)联合钙尔奇D治疗绝经后骨质疏松症的临床疗效。方法58例患者平均年龄为53.65岁,口服福善美70mg(每周1次)和钙尔奇D600mg(每日1次),疗程12个月,于治疗前及治疗后3,6,12月时测定腰椎骨矿密度(BMD)及肝、肾功能,以视觉模拟评分(VAS)法对疼痛进行评定。结果VAS疼痛评分治疗后各时相点均较治疗前显著降低(P<0.01),后一时相点较前一时相点均显著降低(P<0.01);腰椎BMD治疗后各时相点均较治疗前显著增加(P<0.05或0.01);肝、肾功能治疗前后无明显变化。结论福善美联合钙尔奇D治疗绝经后骨质疏松症能显著减轻疼痛、增加腰椎BMD,长期服药不影响肝、肾功能,具有良好的有效性和安全性。
Objective To observe the therapeutic effects of alendronate （Fosamax） combining Callrate D for treating femal postmenopausal osteoporosis. Methods There were 58 female patients suffering postmenopausal osteopornsis with average age of 53.65 years old, The bone mineral density （BMD） of lumbar vertebra,hepalic and renal functions and visual analogue scale （VAS） were measured before treatment for evaluating pain of patients;Fosamax （70 mg/week） and Callrate D （600 mg/d） were taken orally for treating osteoporosis. Above mentioned indexes were measured in 3, 6. 9 and 12 months after treatment. Results The VAS pain evaluation compared with time point before treatment,the score of each time point after treatment dropped obviously （P〈0.01） and the score of latter point was obviously lower than that of the former point （P〈0.01）. The measurement of lumbar vertebra BMD increased after treatment （P 〈0.05 or 0.01）, There was no statistical difference in hepatic and renal functions before or after treatment. Conclusion Fosamax combining Callrate D for treating femal postmenopausal osteoporosis can significantly reduce the pain and increase the lumbar vertebra BMD which is effective and secure.
出处
《中国药业》
CAS
2008年第7期60-61,共2页
China Pharmaceuticals
关键词
骨质疏松症
阿仑膦酸钠
骨矿密度
osteoporosis
alendronate
bone mineral density （BMD）
